Published in final edited form as:

Epilepsy Res. 2018 March ; 141: 1–12. doi:10.1016/j.eplepsyres.2018.01.010.

Dexmedetomidine stops benzodiazepine-refractory nerve agent-induced *status epilepticus*

Hilary S. McCarren^a, Julia A. Arbutus^a, Cherish Ardinger^a, Emily N. Dunn^a, Cecelia E. Jackson^a, and John H. McDonough^a

^aUSAMRICD, Medical Toxicology Research Division, Neuroscience Branch, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, United States

Abstract

Nerve agents are highly toxic chemicals that pose an imminent threat to soldiers and civilians alike. Nerve agent exposure leads to an increase in acetylcholine within the central nervous system, resulting in development of protracted seizures known as *status epilepticus* (SE). Currently, benzodiazepines are the standard of care for nerve agent-induced SE, but their efficacy quickly wanes as the time to treatment increases. Here, we examine the role of the α_2 -adrenoceptor in termination of nerve agent-induced SE using the highly specific agonist dexmedetomidine (DEX). Adult male rats were exposed to soman and entered SE as confirmed by electroencephalograph (EEG). We observed that administration of DEX in combination with the benzodiazepine midazolam (MDZ) 20 or 40 minutes after the onset of SE stopped seizures and returned processed EEG measurements to baseline levels. The protective effect of DEX was blocked by the α_2 -adrenoceptor antagonist atipamezole (ATI), but ATI failed to restore seizure activity after it was already halted by DEX in most cases, suggesting that α_2 -adrenoceptors may be involved in initiating SE cessation rather than merely suppressing seizure activity. Histologically, treatment with DEX + MDZ significantly reduced the number of dying neurons as measured by FluoroJade B in the amygdala, thalamus, and piriform cortex, but did not protect the hippocampus or parietal cortex even when SE was successfully halted. We conclude that DEX serves not just as a valuable potential addition to the anticonvulsant regimen for nerve agent exposure, but also as a tool for dissecting the neural circuitry that drives SE.

Keywords

status epilepticus; dexmedetomidine; α_2 -adrenoceptor; nerve agent; adrenergic; seizure

Corresponding Author: Hilary S. McCarren, hilary.s.mccarren.civ@mail.mil, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010, United States.

Disclaimer: The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, or the U.S. Government.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Since their discovery during World War II, nerve agents have posed a serious, deadly threat to both soldiers and private citizens all over the world. The devastating effects of these agents remain at the forefront of global consciousness even now as multiple sarin attacks have occurred in Syria over the last several years. Nerve agents belong to a class of compounds known as organophosphates that irreversibly bind to and inhibit the enzyme acetylcholinesterase. In the central nervous system, this leads to an abrupt increase in excitatory signaling via acetylcholine that fails to be cleared from synapses. Seizures soon develop and quickly spread throughout the brain, disrupting other neurotransmitter systems and becoming primarily non-cholinergic in nature (McDonough and Shih, 1997). This results in a prolonged state of seizure activity known as *status epilepticus* (SE). Uncontrolled SE carries a significant risk of brain damage and mortality, even when it occurs with direct access to medical care and without major comorbidities (DeLorenzo et al., 2009; Trinka et al., 2015). The prognosis becomes even grimmer in the case of mass casualty chemical attacks, where concurrent trauma, multi-organ involvement, increased time to treatment, and limited resources can all contribute to difficulty in stopping SE (Ben Abraham et al., 2002; Rosman et al., 2014).

The most rational therapeutic target for treating SE has long been considered the GABA_A receptor. Benzodiazepines enhance inhibitory neurotransmission by increasing the affinity of the GABA_A receptor for its endogenous ligand, thus enhancing the likelihood of anion entry into neurons. They are the first-line treatment for SE of any etiology. Despite the effectiveness of benzodiazepines in immediate SE treatment, numerous clinical observations and animal studies have indicated that these drugs become less effective as SE duration increases (Deshpande et al., 2007; Ferlisi and Shorvon, 2012; Lowenstein and Alldredge, 1993; Mazarati et al., 1998; McDonough et al., 2010; Rice and DeLorenzo, 1999; Shih et al., 1999; Walton and Treiman, 1988). This refractoriness is thought to be due to GABA_A receptor internalization and/or changes in the chloride gradient (Deeb et al., 2012). Similar time-dependent loss of anticonvulsant efficacy has been observed for phenobarbital, another drug that potentiates GABA_A receptor activity (Jones et al., 2002). Thus, identifying therapeutic agents that act on non-GABAergic targets could be the key to stopping benzodiazepine-refractory SE.

The adrenergic system has been shown to play an important role in various animal models and clinical manifestations of seizures and SE (Giorgi et al., 2004; Weinshenker and Szot, 2002). Mice that lack norepinephrine are more susceptible to seizures (Szot et al., 1999). Stimulation of the locus coeruleus (LC), a major site of norepinephrine production in the brain, lessens the severity of amygdala-kindled seizures, while destruction of LC terminals converts sporadic seizures into self-sustained SE (Giorgi et al., 2003; Jimenez-Rivera et al., 1987). The rapid depletion of brain norepinephrine levels that follows nerve agent-induced seizures could very well contribute to initiation and/or maintenance of SE in these models (el-Etri et al., 1992; McDonough and Shih, 1997). Though there is some debate in the literature, stimulation of the α 2-adrenoceptor is widely believed to be a major contributor to the protective effects of norepinephrine in seizure models due to its net inhibitory function throughout the central nervous system via both presynaptic and postsynaptic mechanisms

(Giorgi et al., 2004; Weinshenker and Szot, 2002). Multiple studies have demonstrated that α 2-adrenoceptor agonists protect against organophosphate-induced toxicity when administered as pretreatments, though whether this protection is due to central or peripheral effects has not been established (Aronstam et al., 1986; Buccafusco and Aronstam, 1987; Buccafusco and Li, 1992; Yakoub and Mohammad, 1997).

Here we investigated the anticonvulsant and neuroprotective efficacy of the highly specific and potent α 2-adrenoceptor agonist dexmedetomidine (DEX). DEX is FDA approved for sedation and has found utility across a variety of clinical applications (Carollo et al., 2008). DEX has several appealing advantages over other sedative and anesthetic agents. Namely, DEX causes minimal respiratory depression and produces a transiently arousable state that is similar to natural sleep. It has been shown to protect against convulsions, SE, and excitotoxic brain injury in several rodent models, but until now has not been tested against benzodiazepine-refractory or nerve agent-induced SE (Halonen et al., 1995; Kan et al., 2013; Paris et al., 2006; Tanaka et al., 2005; Whittington et al., 2002; Zhai et al., 2016). Additionally, DEX has been shown to act synergistically with the benzodiazepine midazolam (MDZ), thus reducing the dose of each drug required to produce sedation or anxiolysis and reducing cardiovascular and respiratory side effects (Bol et al., 2000; Salonen et al., 1992). We hypothesized that DEX would also enhance the efficacy of MDZ when given at delayed time-points after nerve agent-induced SE onset and protect susceptible brain regions from cell death.

2. Methods

2.1 Animals

This experimental protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the United States Army Medical Research Institute of Chemical Defense, and all procedures were conducted in accordance with the principles stated in the Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act of 1966 (P.L. 89-544), as amended. Male Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 250–300 g prior to surgery were used for this study (n = 142). They were housed in individual cages in a temperature- and humidity- controlled room with a 12-hour light-dark cycle (lights on at 06:00). Food and water were available *ad libitum* except during experimental periods. In order to reduce the number of animals that must undergo unmitigated nerve agent-induced SE, the animals treated with MDZ + saline have served as controls across multiple studies. Their raw EEG and histopathology data have been previously analyzed and reported (Althaus et al., 2017).

2.2 Drugs

Drugs that were purchased in solid form were dissolved in 0.9% saline solution and passed through a 0.22 μ m sterile filter prior to administration. HI-6 was synthesized by Kalexsyn Medicinal Chemistry (Kalamazoo, MI) and prepared at 250 mg/ml. Atropine methyl nitrate (AMN) was synthesized by Wedgewood Pharmacy (Swedesboro, NJ) and prepared at 4 mg/ml. Soman was synthesized by the US Army Edgewood Chemical Biological Center (Aberdeen Proving Ground, MD) and diluted to 360 μ g/ml. Atropine sulfate from Sparhawk

Laboratories Inc. (Lenexa, KS) was admixed with 2-PAM from Baxter Healthcare Corporation (Deerfield, IL) at final concentrations of 0.9 mg/ml and 50 mg/ml respectively. DEX, ATI, and MDZ were all purchased as pre-formulated USP-grade sterile solutions in saline. DEX and ATI were made by Orion Corporation (Espoo, Finland) at concentrations of 0.5 mg/ml and 5 mg/ml respectively. Midazolam was made by Akorn Inc. (Lake Forest, IL) at 5 mg/ml.

2.3 EEG Implant Surgery

Surgery to implant cortical electroencephalographic (EEG) electrodes was performed as previously described (Althaus et al., 2017). Stainless steel screw electrodes were placed over cerebellum and each hemisphere of the parietal cortex. Animals were allowed to recover for 5–7 days before experimentation.

2.4 Nerve Agent Exposure

At approximately 07:00 on experiment day, animals were placed in individual recording chambers and connected to the EEG recording system via their implanted plug. At least 60 minutes of normal baseline EEG activity was recorded prior to nerve agent exposure. To promote survival until development of neurological symptoms was observed, it was necessary to protect animals from peripheral nerve agent toxicity by administering 125 mg/kg HI-6 intraperitoneally (IP) 30 minutes before nerve agent and 2 mg/kg AMN intramuscularly (IM) 1 minute after nerve agent. Even with these countermeasures, 41 animals (29%) died prior to treatment with test compounds and were excluded from all analyses. The nerve agent soman was delivered SC at a dose of 180 µg/kg, which elicited SE in 100% of animals studied. Onset of SE was defined by the appearance on the EEG of repetitive spikes and sharp waves with an amplitude greater than twice that of the baseline and a duration of at least 10 seconds. At 20 or 40 minutes after onset of SE, animals were treated with 0.45 mg/kg atropine sulfate admixed with 25 mg/kg, 2-PAM (IM), the designated dose of test compound (saline or DEX at 0.1, 0.2, or 0.4 mg/kg), and, where indicated, 1.8 mg/kg MDZ (IM). For the blocking and reversal experiments, animals received MDZ + 0.4 mg/kg DEX at 20 minutes after SE onset and 4 mg/kg ATI either 5 minutes before MDZ + DEX (blocking) or 10 minutes after SE cessation (reversal). Following treatment, EEG activity was recorded for at least 4 hours, after which the EEG was visually evaluated for evidence of seizure activity. If intermittent or ongoing spiking was observed, the animal was euthanized for collection of brain tissue (see below). This was considered the most humane endpoint for animals in which treatment had failed to provide permanent SE termination. If the EEG record of a given animal displayed no evidence of epileptiform activity, the animal was returned to its home cage. The next morning, 24 hours after soman exposure, those animals were again connected to the recording system, and at least 30 min of EEG signal was recorded to confirm whether seizure activity had returned. Following this recording session the animals were euthanized for collection of brain tissue.

2.5 EEG recording and analysis

EEG signals were passed through 1902 amplifiers, digitized with a Micro1401 data acquisition interface, and recorded and visualized with Spike2 software (all from Cambridge Electronic Design Limited, Cambridge, England). Data channels were sampled at 512 Hz

and digitally filtered with a high-pass 0.3 Hz filter, a low-pass 100 Hz filter, and a 60 Hz notch filter. Two animals were excluded from EEG analysis due to excessive, transient noise throughout their recording session (see Supplemental Table 1). Visual scoring of SE onset, termination, and re-onset required consensus of two experienced individuals. Termination was defined as reduction of EEG amplitude to less than twice that of baseline coupled with cessation of rhythmic spiking activity lasting for at least 5 minutes. Re-onset was defined as any instance of repetitive spikes or sharp waves exceeding an amplitude of twice that of baseline. Spike rate and gamma band power (20–60 Hz) were calculated using custom Python-based software (Lehmkuhle et al., 2009; White et al., 2006). Values were obtained for 5-minute epochs with a 50% overlap sliding window. For both measures, the software automatically identified 10 minutes of optimal noise-free baseline activity prior to soman administration for each animal and calculated the difference between the mean spike rate or gamma power value for this period and the values for all other epochs. This accounts for differences in signal strength between animals in the same treatment group. Data were reported as the mean change from baseline $\pm$ standard error of the mean for each treatment group. Means and standard errors were calculated based on all animals in a treatment group, regardless of anticonvulsant outcome.

2.6 Tissue Preparation and Histopathology

Following the EEG recording session, animals were transcardially perfused with saline and 10% formalin, and tissue was prepared as previously described (Althaus et al., 2017). A 5 μ m thick section corresponding to 3.24 mm posterior to bregma was slide-mounted for FluoroJade B (FJB) staining according to published protocols (Paxinos and Watson, 2007; Schmued and Hopkins, 2000). Images of the stained slices were captured using an Olympus VS120-L100-W virtual slide microscope and VS-ASW software (Olympus Corporation, Tokyo, Japan). FIJI was used to crop out regions of interest for neuropathology using the following dimensions (width $\times$ height): amygdala (1000 μ m $\times$ 1000 μ m), piriform cortex (200 μ m $\times$ 2000 μ m), thalamus (1000 μ m $\times$ 1300 μ m), and parietal cortex (1500 μ m $\times$ 2000 μ m). The hippocampus counting region was defined by the anatomical boundaries of the structure. A treatment-blinded technician counted the number of FluoroJade B-expressing cells in each cropped region.

2.7 Statistics

In addition to the 41 animals that died prior to treatment, 26 treated animals were excluded from EEG and/or histopathological analysis. The reason for exclusions and distribution across groups is detailed in Supplemental Table 1. Values for change in spike rate and gamma power relative to baseline for each treatment group of interest were compared at selected time points (20 minutes before SE onset, at treatment time, and at hours 1, 2, 3, and 4 after SE onset) using either unpaired t-tests when two groups were compared or one-way ANOVAs when three or more groups were compared. For significant ANOVAs, Tukey's comparison was used to evaluate differences between each group. Latency to re-onset of SE in the presence or absence of the reversal agent was compared using an unpaired t-test. Similarly, mean FluoroJade B cell counts in each of 5 brain regions for treatment groups of interest were compared by t-test or one-way ANOVA with a Tukey comparison. For all statistical evaluations, $p < 0.05$ was considered significant.

3. Results

3.1 Treatment at 20 minutes after SE onset with MDZ + DEX rapidly terminates seizures

In all EEG experiments described, both spike rate and gamma power relative to baseline were used as a quantitative measure of anticonvulsant efficacy. Values at or below zero generally corresponded with seizure cessation based on visual evaluation. Three doses of DEX (0.1, 0.2, and 0.4 mg/kg) were tested as co-treatments with MDZ at 20 minutes after SE onset. These doses were chosen based on previous research showing that 0.5 mg/kg is the approximate intraperitoneal ED₉₉ for DEX-induced sedation in rats (Doze et al., 1989). MDZ + 0.4 mg/kg DEX (n = 9) led to rapid termination of SE in 100% of animals tested, while only 1 animal in the MDZ + saline group (n = 12) had a brief, delayed SE cessation (Table 1). Lower doses of DEX also led to SE termination in the majority of animals tested: 83% for MDZ + 0.2 mg/kg DEX (n = 12) and 66% for MDZ + 0.1 mg/kg DEX (n = 9). MDZ + DEX dose-dependently decreased both normalized spike rate and gamma power relative to MDZ + saline controls (Figure 1). Full lists of p-values for the spike rate and gamma power analyses for all experiments are shown in Tables 2 & 3. For both measures, a significant effect of treatment was observed at hours 1–4 after SE onset, but not during baseline or at treatment time. Dose-dependent anticonvulsant efficacy was observed, with the MDZ + 0.1 mg/kg DEX group differing significantly from all others at several time points.

3.2 Treatment at 40 minutes after SE onset with MDZ + DEX suppresses seizures

To determine if DEX enhances the anticonvulsant efficacy of MDZ at a longer treatment delay, animals were administered MDZ + 0.4 mg/kg DEX (n = 8) or MDZ + saline (n = 9) at 40 minutes after SE onset. Of animals treated with MDZ + DEX, 75% had SE termination, while no animals treated with MDZ + saline stopped seizing (Table 1). Though SE termination in the MDZ + DEX-treated animals was not permanent, all animals remained seizure-free for at least 3 hours. Treatment with MDZ + DEX also led to reduced spike rate and gamma power compared to control animals at hours 2 & 3 (both measures) & 4 (gamma power only; Figure 2, Tables 2 & 3).

3.3 Treatment at 20 minutes after SE onset with DEX alone causes a delayed effect on EEG activity

Having demonstrated clear anticonvulsant efficacy of MDZ + DEX, we next sought to determine whether DEX alone could terminate soman-induced SE. Animals were treated with 0.4 mg/kg DEX without concurrent MDZ at 20 minutes after SE onset (n = 10). Of the animals treated with DEX alone, 60% demonstrated a marked drop in EEG amplitude and high frequency oscillations at approximately 3 hours after treatment (Figure 3), with half of those animals having SE termination around this time (Table 1). This is reflected in the group means of spike rate and gamma power, which were significantly lower than those of animals treated with MDZ + saline at hours 3 & 4 for both measures (Tables 2 & 3).

3.4 Blockade of MDZ + DEX with ATI increases mortality and reduces anticonvulsant efficacy

ATI is used to reverse the sedative and hypotensive effects of DEX in veterinary medicine by acting as an antagonist at the α_2 -adrenoceptor. Here we used ATI as both a blocking agent (administered before MDZ + 0.4 mg/kg DEX) and a reversal agent (administered after SE termination caused by MDZ + 0.4 mg/kg DEX) in order to query the mechanism by which DEX stops SE. When used as a blocking agent, ATI led to post-treatment mortality in 67% of animals ($n = 8$ died out of $n = 12$ treated). In animals that survived the 4-hour EEG recording period ($n=5$), SE terminated 15 minutes after MDZ + DEX administration in a single animal, but this animal died after the recording had ended. No seizure cessation was observed for the remainder of the group. As a group, the five included animals from the blocking experiment had a significantly lower relative spike rate than animals treated with MDZ + saline at hours 1 and 2 and did not differ from animals treated with MDZ + 0.4 mg/kg DEX (Figure 4, Tables 2 & 3). Relative gamma power for the blocking group differed from both MDZ + saline at hours 1–3 and from MDZ + 0.4 mg/kg DEX at hours 1–4. Given the low number of survivors in the blocking experiment, the apparent improvements in quantitative EEG measures compared to MDZ + saline are likely driven by the single animal in which SE terminated. It is not possible to determine whether data from the blocking group is normally distributed, but nonparametric Kruskal-Wallis analyses of both spike rate and gamma power reveal no significant differences between either the MDZ + 0.4 mg/kg DEX or the MDZ + saline groups and the blocking group at any time point.

3.5 ATI is largely ineffective at reversing the anticonvulsant effect of MDZ + DEX after SE has terminated

Use of ATI as a reversal agent was mostly, but not completely, ineffective at restoring seizure activity (Figure 5). In 7 of the 10 animals treated with ATI after MDZ + DEX, SE did not return for the duration of the experiment. However, in the remaining three animals, SE resumed shortly after ATI administration. The latency to re-onset in these animals was 36 ± 21 minutes, while animals that had temporary SE cessation after treatment with MDZ + 0.4 mg/kg DEX in the absence of a reversal agent had a significantly higher latency to re-onset of 189 ± 22 minutes ($p = 0.0046$). In all animals that received ATI as a reversal agent, an abrupt change in EEG activity was observed following ATI administration. Low amplitude, high frequency activity replaced the high amplitude delta waves that are characteristic of DEX-induced sedation. Relative spike rate for the reversal group was significantly lower than the MDZ + saline group at hours 1 and 2 but did not differ from the MDZ + 0.4 mg/kg DEX group throughout the experiment (Table 2). Gamma power for the reversal group differed from both the MDZ + saline and the MDZ + 0.4 mg/kg DEX groups each hour after treatment (Table 3).

3.6 Treatment with DEX selectively protects the amygdala, thalamus, and piriform cortex

FJB is a histological marker for dying neurons and was used in this study to determine whether DEX could reduce pathology relative to animals treated at the same time point with MDZ + saline. Outlines of the regions of interest and cell counts for each experimental group are shown in Figure 6. The p-values for all histopathology analyses are available in

Table 4. Overall, DEX consistently reduced the number of FJB-positive neurons in the amygdala, thalamus, and piriform cortex, but not in the hippocampus or parietal cortex. This pattern was observed after treatment with MDZ + DEX 20 minutes and 40 minutes after SE onset. Unlike quantitative EEG measures, all doses in the 20-minute treatment group were equally effective. Treatment with DEX alone at 20 minutes after SE onset significantly reduced FJB in the amygdala and thalamus, and approached significance in the piriform cortex. Though the number of animals that survived to histopathology was very small in the blocking experiment, administration of ATI before DEX still led to significantly higher FJB counts in the amygdala and piriform cortex than when the MDZ + 0.4 mg/kg DEX treatment was administered alone. In similar accordance with EEG experiments, ATI also failed to reverse the protective effect of DEX on the amygdala, thalamus, and piriform cortex.

4. Discussion

There is significant support for a therapeutic role of α_2 -adrenoceptor stimulation in organophosphate-induced toxicity, seizures, and neuronal excitotoxicity. Our data demonstrate that the α_2 -adrenoceptor agonist DEX confers substantial anticonvulsant activity and neuroprotection even when treatment of soman-induced SE is delayed to realistic mass casualty first-responder time points. We have recapitulated previous findings that a treatment delay of as little as 20 minutes is enough to render nerve agent-induced SE refractory to treatment with a benzodiazepine (McDonough et al., 2010). The dose of MDZ used in our study, 1.8 mg/kg, is the rat-scaled equivalent of two 10 mg auto-injectors in an adult human. This is twice the prehospital dose of MDZ that was found effective against SE in the RAMPART study (Food and Drug Administration, 2005; Silbergleit et al., 2012). In an effort to approximate clinically relevant dosing of DEX, we chose doses that spanned the effective range for sedation in rats and were well below the maximum tolerated dose of at least 3 mg/kg (Doze et al., 1989). Since we also observed dose-dependent anticonvulsant efficacy over this range, it is reasonable to predict that the two endpoints might share a similar clinical dosing strategy. It will be important in future studies to determine whether the tested doses of DEX + MDZ are similarly efficacious in females and the elderly because there have been reports of menstrual cycle effects on depth of DEX sedation and age-sex interactions on DEX absorption kinetics (Kuang et al., 2015; Zhou et al., 2014).

DEX may also help to alleviate some of the peripheral symptoms of nerve agent poisoning. We found that animals that received DEX displayed a marked reduction in peripheral muscle convulsions, which is consistent with previous observations that DEX inhibits muscle contractions, purportedly by inhibiting acetylcholine release (Mikami et al., 2017; Rakovska, 1993; Tarkovacs et al., 1990). There is clinical evidence that α_2 -adrenoceptor agonists can also reduce gastric and salivary secretions, which are characteristic signs of nerve agent poisoning (DiJoseph et al., 1984; McArthur et al., 1982; Watkins et al., 1980). Additionally, DEX has well-characterized analgesic properties that would make it a particularly attractive therapy for cases that involve concurrent injury or trauma. The primary complications associated with traditional clinical use of DEX are bradycardia and hypotension. Though heart rate and blood pressure were not measured in this experiment, atropine is known to have opposing cardiovascular effects during soman intoxication, which may have helped to minimize the potential for adverse events (Lipp, 1976).

The apparent mutual enhancement of anticonvulsant efficacy that DEX and MDZ exert upon each other suggests that the two drugs would be best used as a co-therapy, with MDZ rapidly suppressing SE and DEX offering delayed but longer-lasting anticonvulsant effects. This kind of rational polypharmacy approach is gaining ground as several researchers are showing better control of seizures with fewer side effects after combination therapies in animal models (Brandt et al., 2015; Loscher and Honack, 1994; Niquet et al., 2017; Wasterlain et al., 2011). The increased seizure control that comes from targeting multiple neurotransmitter systems might be attributable to heterogeneity in the neural mechanisms that initiate and drive SE between individuals. Such variability, combined with use of an outbred rat strain and variable absorption of DEX by the IP administration route, could explain why some of the animals in our study treated with MDZ + 0.4 mg/kg DEX had reemergence of SE.

On the other hand, we observed that more than half of the animals treated with MDZ + 0.4 mg/kg DEX remained seizure-free 24 hours after treatment, at which point sedative effects have long worn off (Doze et al., 1989). This finding lends support to the theory that stimulation of α_2 -adrenoceptors can initiate a cascade of events that lead to true seizure control rather than just temporary dampening of brain-wide excitability. This notion is further supported by the results of the reversal and blocking experiments. When ATI was delivered shortly after MDZ + DEX had already stopped SE, most animals remained seizure-free. When α_2 -adrenoceptors were blocked by ATI, DEX was far less effective at stopping SE. In fact, the majority of animals in this experiment died after treatment, whereas no post-treatment mortality was observed when DEX and ATI were delivered in the opposite order. Though DEX's affinity for α_2 -adrenoceptors is approximately 1600-fold higher than for α_1 -adrenoceptors, pretreatment with ATI should lead to a higher concentration of free extracellular DEX. In such conditions, DEX will bind to α_1 -adrenoceptors, leading to functional antagonism of sedation (Guo et al., 1991; Schwinn et al., 1991). It is difficult to predict how α_1 -adrenoceptor stimulation by DEX might affect the compromised cardiovascular and sympathetic nervous systems of a nerve agent-poisoned animal, but this seems to be the most likely explanation for the mortality we observed in this experiment.

The reversal experiment also provided valuable information about the role of α_2 -adrenoceptors in brain excitability. We observed a rapid return of wake-like EEG activity after ATI administration that, in most cases, did not lead to the return of SE. In several animals, righting reflex was restored, and they began to ambulate. The ability to rapidly terminate SE and then restore arousal would be very useful in an emergency scenario, especially on the frontlines of a war zone. Though ATI has not been FDA-approved for human use, several studies have demonstrated safety and efficacy as a sedative reversal agent in volunteers (Aho et al., 1993; Huupponen et al., 1995; Karhuvaara et al., 1991; Scheinin et al., 1998). Even without a clinically available reversal agent, DEX is an attractive potential countermeasure because of its intrinsic temporary sedative reversibility following strong sensory stimuli. Such a characteristic has not been described for any other experimental or proven anticonvulsant therapy.

Despite observing anticonvulsant efficacy in 100% of animals treated with 0.4 mg/kg DEX + MDZ, histopathological analysis of vulnerable brain regions demonstrated a reduction in

FluoroJade B-positive cells only in the amygdala, thalamus, and piriform cortex. One possible explanation for this effect is direct targeting of $\alpha 2$ -adrenoceptors on neurons in these areas. Moderate to high levels of $\alpha 2$ -adrenoceptor mRNA have been detected in the amygdala, piriform cortex, thalamus, and hippocampus of rodents (MacDonald and Scheinin, 1995; Wang et al., 1996). Direct application of $\alpha 2$ -adrenoceptor agonists to amygdala, thalamus, and piriform cortex has been shown to inhibit cellular activity (DeBock et al., 2003; Ferry et al., 1997; Gellman and Aghajanian, 1993; Kamisaki et al., 1992) and, in the case of the amygdala, provide functional protection against seizures (Pelletier and Corcoran, 1993; Shouse et al., 1996). Additionally, noradrenergic grafts in the amygdala and piriform cortex but not the hippocampus suppress kindling, suggesting that adrenoceptors do not play a major protective role in that region (Barry et al., 1989). Given the apparent secondary role of the hippocampus in nerve agent-induced seizures compared to the amygdala (Aroniadou-Anderjaska et al., 2009), it is not unreasonable that we observed SE termination without full protection of the hippocampus.

The timing of our histopathological assessment could also have contributed to the similarity in FJB counts for control- and DEX-treated animals in the hippocampus and parietal cortex. Organophosphate-induced neuronal damage in the amygdala, thalamus, and piriform cortex has been observed shortly after exposure (Baille et al., 2005; Carpentier et al., 2000; Lemerrier et al., 1983; McDonough et al., 1995), while damage in the hippocampus and cerebral cortex does not peak until hours to days after the chemical insult (Deshpande et al., 2008; Hobson et al., 2017; Li et al., 2011; McLeod et al., 1984; Siso et al., 2017). Since our control animals were euthanized at 4 hours after SE onset, analysis may have preempted much of the potential neuronal death in the hippocampus and parietal cortex, making any treatment-related improvement difficult to detect. Whether or not the regional selectivity of our histopathological findings is affected by sampling time, the reduced FJB counts in multiple brain areas of animals treated with low doses of MDZ + DEX and with DEX alone suggest that $\alpha 2$ -adrenoceptor stimulation can serve a therapeutic role even at sub-anticonvulsant doses. This critical observation makes a strong argument for further investigation of the neural circuitry involved in nerve agent-induced SE and subsequent brain damage.

5. Conclusions

Our data demonstrate that DEX is an excellent candidate for further development as a nerve agent countermeasure. Its ability to enhance the anticonvulsant effect of midazolam when administered at delayed time points is an attractive feature not just in the context of chemical exposures, but also in the treatment of SE of any etiology. Extensive studies have already been done on DEX's safety and efficacy as a sedative in both children and adults. It is well-absorbed via intramuscular, intranasal, and buccal routes in humans, so it could realistically be delivered in the field alongside MDZ auto-injectors (Anttila et al., 2003; Dyck et al., 1993; Iirola et al., 2011; Yoo et al., 2015). DEX is currently manufactured on a large scale and stands at the ready in hospitals all over the world. Its favorable respiratory profile, beneficial peripheral effects, and reversibility make DEX truly unique and potentially superior to traditional anticonvulsant nerve agent countermeasures. On top of DEX's efficacy, its specificity for $\alpha 2$ -adrenoceptors provides a rare and valuable tool to help us

understand more about which brain regions and/or neural circuits drive SE control. This knowledge will allow us to rationally pursue therapies that are the most efficacious at early and late stages of nerve agent-induced SE without risking unnecessary side effects, thereby providing better care for anyone that falls victim to these deadly chemicals.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Dave Jett, Dave Yeung, and the CounterACT Neurotherapeutic Screening program for providing preliminary efficacy data for DEX + MDZ. Additional thanks to Aymen Alqazzaz, Denny Ballough, Sergiu Costinas, Haneef Craig, Wafae Driwech, Kari Haines, Ashley Hubbard, Ryan Krempel, Hunter Martin, Emylee McFarland, Craig Oppel, Toni Santoro, and Josh Vaughan and for their technical contributions to the project, as well as to Kristin Winter for managerial assistance.

Funding: This research was supported in part by appointments to the Postgraduate Research Participation Program at the U.S. Army Medical Research Institute of Chemical Defense administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and U.S. Army Medical Research and Materiel Command. Support was also provided by the NIH Office of the Director through an Inter-Agency Agreement (Y1-O6-9613-01) between the National Institute of Allergy and Infectious Diseases (NIAID) and Department of Defense USAMRICD (A120-B.P2009-2).

Abbreviations

SE	<i>status epilepticus</i>
GABA	γ -aminobutyric acid
LC	locus coeruleus
DEX	dexmedetomidine
MDZ	midazolam
ATI	atipamezole

References

- Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Comparison of dexmedetomidine and midazolam sedation and antagonism of dexmedetomidine with atipamezole. *Journal of clinical anesthesia*. 1993; 5:194–203. [PubMed: 8100428]
- Althaus AL, McCarren HS, Alqazzaz A, Jackson C, McDonough JH, Smith CD, Hoffman E, Hammond RS, Robichaud AJ, Doherty JJ. The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication. *Epilepsy & behavior: E&B*. 2017; 68:22–30.
- Anttila M, Penttilä J, Helminen A, Vuorilehto L, Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. *British journal of clinical pharmacology*. 2003; 56:691–693. [PubMed: 14616431]
- Aroniadou-Anderjaska V, Figueiredo TH, Apland JP, Qashu F, Braga MF. Primary brain targets of nerve agents: the role of the amygdala in comparison to the hippocampus. *Neurotoxicology*. 2009; 30:772–776. [PubMed: 19591865]
- Aronstam RS, Smith MD, Buccafusco JJ. Clonidine protection from soman and echothiophate toxicity in mice. *Life sciences*. 1986; 39:2097–2102. [PubMed: 3784771]

- Baille V, Clarke PG, Brochier G, Dorandeu F, Verna JM, Four E, Lallement G, Carpentier P. Soman-induced convulsions: the neuropathology revisited. *Toxicology*. 2005; 215:1–24. [PubMed: 16054742]
- Barry DI, Wanscher B, Kragh J, Bolwig TG, Kokaia M, Brundin P, Bjorklund A, Lindvall O. Grafts of fetal locus coeruleus neurons in rat amygdala-piriform cortex suppress seizure development in hippocampal kindling. *Experimental neurology*. 1989; 106:125–132. [PubMed: 2509233]
- Ben Abraham R, Rudick V, Weinbroum AA. Department of, A., Critical Care Medicine, T.A.S.M.C., the Sackler Faculty of, M. Practical guidelines for acute care of victims of bioterrorism: conventional injuries and concomitant nerve agent intoxication. *Anesthesiology*. 2002; 97:989–1004. [PubMed: 12357169]
- Bol CJ, Vogelaar JP, Tang JP, Mandema JW. Quantification of pharmacodynamic interactions between dexmedetomidine and midazolam in the rat. *The Journal of pharmacology and experimental therapeutics*. 2000; 294:347–355. [PubMed: 10871332]
- Brandt C, Tollner K, Klee R, Broer S, Loscher W. Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpine model in rats: Window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers. *Neurobiology of disease*. 2015; 75:78–90. [PubMed: 25549873]
- Buccafusco JJ, Aronstam RS. Adrenergic agonists protect against soman, an irreversible acetylcholinesterase inhibitor. *Toxicology letters*. 1987; 38:67–76. [PubMed: 2820088]
- Buccafusco JJ, Li W. Effectiveness of alpha 2-adrenergic receptor stimulation in reducing the central toxicity following cholinesterase inhibition. *Research communications in chemical pathology and pharmacology*. 1992; 75:85–98. [PubMed: 1352646]
- Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. *Current opinion in anaesthesiology*. 2008; 21:457–461. [PubMed: 18660652]
- Carpentier P, Foquin A, Rondouin G, Lerner-Natoli M, de Groot DM, Lallement G. Effects of atropine sulphate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology. *Neurotoxicology*. 2000; 21:521–540. [PubMed: 11022861]
- DeBock F, Kurz J, Azad SC, Parsons CG, Hapfelmeier G, Zieglansberger W, Rammes G. Alpha2-adrenoreceptor activation inhibits LTP and LTD in the basolateral amygdala: involvement of Gi/o-protein-mediated modulation of Ca²⁺-channels and inwardly rectifying K⁺-channels in LTD. *The European journal of neuroscience*. 2003; 17:1411–1424. [PubMed: 12713644]
- Deeb TZ, Maguire J, Moss SJ. Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. *Epilepsia*. 2012; 53(Suppl 9):79–88.
- DeLorenzo RJ, Kirmani B, Deshpande LS, Jakkampudi V, Towne AR, Waterhouse E, Garnett L, Ramakrishnan V. Comparisons of the mortality and clinical presentations of status epilepticus in private practice community and university hospital settings in Richmond, Virginia. *Seizure*. 2009; 18:405–411. [PubMed: 19324574]
- Deshpande LS, Blair RE, Nagarkatti N, Sombati S, Martin BR, DeLorenzo RJ. Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus. *Experimental neurology*. 2007; 204:705–713. [PubMed: 17289026]
- Deshpande LS, Lou JK, Mian A, Blair RE, Sombati S, Attkisson E, DeLorenzo RJ. Time course and mechanism of hippocampal neuronal death in an in vitro model of status epilepticus: role of NMDA receptor activation and NMDA dependent calcium entry. *European journal of pharmacology*. 2008; 583:73–83. [PubMed: 18289526]
- DiJoseph JF, Taylor JA, Mir GN. Alpha-2 receptors in the gastrointestinal system: a new therapeutic approach. *Life sciences*. 1984; 35:1031–1042. [PubMed: 6148675]
- Doze VA, Chen BX, Maze M. Dexmedetomidine produces a hypnotic-anesthetic action in rats via activation of central alpha-2 adrenoceptors. *Anesthesiology*. 1989; 71:75–79. [PubMed: 2568769]
- Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. *Anesthesiology*. 1993; 78:813–820. [PubMed: 8098190]
- el-Etri MM, Nickell WT, Ennis M, Skau KA, Shipley MT. Brain norepinephrine reductions in soman-intoxicated rats: association with convulsions and AChE inhibition, time course, and relation to other monoamines. *Experimental neurology*. 1992; 118:153–163. [PubMed: 1426125]

- Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. *Brain: a journal of neurology*. 2012; 135:2314–2328. [PubMed: 22577217]
- Ferry B, Magistretti PJ, Pralong E. Noradrenaline modulates glutamate-mediated neurotransmission in the rat basolateral amygdala in vitro. *The European journal of neuroscience*. 1997; 9:1356–1364. [PubMed: 9240393]
- Food and Drug Administration. Research CfDEa. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD: 2005.
- Gellman RL, Aghajanian GK. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. *Brain research*. 1993; 600:63–73. [PubMed: 8422591]
- Giorgi FS, Ferrucci M, Lazzeri G, Pizzanelli C, Lenzi P, Alessandri MG, Murri L, Fornai F. A damage to locus coeruleus neurons converts sporadic seizures into self-sustaining limbic status epilepticus. *The European journal of neuroscience*. 2003; 17:2593–2601. [PubMed: 12823466]
- Giorgi FS, Pizzanelli C, Biagioni F, Murri L, Fornai F. The role of norepinephrine in epilepsy: from the bench to the bedside. *Neuroscience and biobehavioral reviews*. 2004; 28:507–524. [PubMed: 15465138]
- Guo TZ, Tinklenberg J, Oliker R, Maze M. Central alpha 1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist. *Anesthesiology*. 1991; 75:252–256. [PubMed: 1677547]
- Halonen T, Kotti T, Tuunanen J, Toppinen A, Miettinen R, Riekkinen PJ. Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. *Brain research*. 1995; 693:217–224. [PubMed: 8653412]
- Hobson BA, Siso S, Rowland DJ, Harvey DJ, Bruun DA, Garbow JR, Lein PJ. Magnetic Resonance Imaging Reveals Progressive Brain Injury in Rats Acutely Intoxicated with Diisopropylfluorophosphate. *Toxicological sciences: an official journal of the Society of Toxicology*. 2017
- Huupponen R, Karhuvaara S, Anttila M, Vuorilehto L, Scheinin H. Buccal delivery of an alpha 2-adrenergic receptor antagonist, atipamezole, in humans. *Clinical pharmacology and therapeutics*. 1995; 58:506–511. [PubMed: 7586944]
- Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT. Bioavailability of dexmedetomidine after intranasal administration. *European journal of clinical pharmacology*. 2011; 67:825–831. [PubMed: 21318594]
- Jimenez-Rivera C, Voltura A, Weiss GK. Effect of locus ceruleus stimulation on the development of kindled seizures. *Experimental neurology*. 1987; 95:13–20. [PubMed: 3792474]
- Jones DM, Esmaeil N, Maren S, Macdonald RL. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. *Epilepsy research*. 2002; 50:301–312. [PubMed: 12200221]
- Kamisaki Y, Hamahashi T, Hamada T, Maeda K, Itoh T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. *European journal of pharmacology*. 1992; 217:57–63. [PubMed: 1356800]
- Kan MC, Wang WP, Yao GD, Li JT, Xie T, Wang W, Ma WQ. Anticonvulsant effect of dexmedetomidine in a rat model of self-sustaining status epilepticus with prolonged amygdala stimulation. *Neuroscience letters*. 2013; 543:17–21. [PubMed: 23578603]
- Karhuvaara S, Kallio A, Salonen M, Tuominen J, Scheinin M. Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers. *British journal of clinical pharmacology*. 1991; 31:160–165. [PubMed: 1675577]
- Kuang Y, Zhang RR, Pei Q, Tan HY, Guo CX, Huang J, Xiang YX, Ouyang W, Duan KM, Wang SY, Yang GP. Pharmacokinetic and pharmacodynamic study of dexmedetomidine in elderly patients during spinal anesthesia. *International journal of clinical pharmacology and therapeutics*. 2015; 53:1005–1014. [PubMed: 26413731]

- Lehmkuhle MJ, Thomson KE, Scheerlinck P, Pouliot W, Greger B, Dudek FE. A simple quantitative method for analyzing electrographic status epilepticus in rats. *J Neurophysiol.* 2009; 101:1660–1670. [PubMed: 19129295]
- Lemercier G, Carpentier P, Sentenac-Roumanou H, Morelis P. Histological and histochemical changes in the central nervous system of the rat poisoned by an irreversible anticholinesterase organophosphorus compound. *Acta neuropathologica.* 1983; 61:123–129. [PubMed: 6637396]
- Li Y, Lein PJ, Liu C, Bruun DA, Tewolde T, Ford G, Ford BD. Spatiotemporal pattern of neuronal injury induced by DFP in rats: a model for delayed neuronal cell death following acute OP intoxication. *Toxicology and applied pharmacology.* 2011; 253:261–269. [PubMed: 21513723]
- Lipp JA. Effect of atropine upon the cardiovascular system during soman-induced respiratory depression. *Archives internationales de pharmacodynamie et de therapie.* 1976; 220:19–27. [PubMed: 821408]
- Loscher W, Honack D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. *European journal of pharmacology.* 1994; 259:R3–5. [PubMed: 7957602]
- Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. *Neurology.* 1993; 43:483–488. [PubMed: 8450988]
- MacDonald E, Scheinin M. Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. *Journal of physiology and pharmacology: an official journal of the Polish Physiological Society.* 1995; 46:241–258. [PubMed: 8527807]
- Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. *Brain research.* 1998; 814:179–185. [PubMed: 9838100]
- McArthur KE, Anderson DS, Durbin TE, Orloff MJ, Dharmasathaphorn K. Clonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer. *Annals of internal medicine.* 1982; 96:323–325. [PubMed: 7059095]
- McDonough JH Jr, Dochterman LW, Smith CD, Shih TM. Protection against nerve agent-induced neuropathology, but not cardiac pathology, is associated with the anticonvulsant action of drug treatment. *Neurotoxicology.* 1995; 16:123–132. [PubMed: 7603632]
- McDonough JH Jr, Shih TM. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. *Neuroscience and biobehavioral reviews.* 1997; 21:559–579. [PubMed: 9353792]
- McDonough JH, McMonagle JD, Shih TM. Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs. *Drug Chem Toxicol.* 2010; 33:279–283. [PubMed: 20429808]
- McLeod CG Jr, Singer AW, Harrington DG. Acute neuropathology in soman poisoned rats. *Neurotoxicology.* 1984; 5:53–57.
- Mikami M, Zhang Y, Kim B, Worgall TS, Groeben H, Emala CW. Dexmedetomidine's inhibitory effects on acetylcholine release from cholinergic nerves in guinea pig trachea: a mechanism that accounts for its clinical benefit during airway irritation. *BMC anesthesiology.* 2017; 17:52. [PubMed: 28356076]
- Niquet J, Baldwin R, Suchomelova L, Lumley L, Eavey R, Wasterlain CG. Treatment of experimental status epilepticus with synergistic drug combinations. *Epilepsia.* 2017
- Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. *Anesthesia and analgesia.* 2006; 102:456–461. [PubMed: 16428542]
- Paxinos G, Watson C. *The Rat Brain in Stereotaxic Coordinates.* 6. Academic Press; London; Amsterdam; Burlington, MA: 2007.
- Pelletier MR, Corcoran ME. Infusions of alpha-2 noradrenergic agonists and antagonists into the amygdala: effects on kindling. *Brain research.* 1993; 632:29–35. [PubMed: 7908598]
- Rakovska AD. Functional and neurochemical evidence that neurotensin-induced release of acetylcholine from Auerbach's plexus of guinea-pig ileum is presynaptically controlled via alpha 2-adrenoceptors. *Neurochemical research.* 1993; 18:737–741. [PubMed: 8103576]
- Rice AC, DeLorenzo RJ. N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. *Neuroscience.* 1999; 93:117–123. [PubMed: 10430476]

- Rosman Y, Eisenkraft A, Milk N, Shiyovich A, Ophir N, Shrot S, Kreiss Y, Kassirer M. Lessons learned from the Syrian sarin attack: evaluation of a clinical syndrome through social media. *Annals of internal medicine*. 2014; 160:644–648. [PubMed: 24798526]
- Salonen M, Onaivi ES, Maze M. Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats. *Psychopharmacology*. 1992; 108:229–234. [PubMed: 1357706]
- Scheinin H, Aantaa R, Anttila M, Hakola P, Helminen A, Karhuvaara S. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. *Anesthesiology*. 1998; 89:574–584. [PubMed: 9743392]
- Schmued LC, Hopkins KJ, Flouro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. *Brain Res*. 2000; 874:123–130. [PubMed: 10960596]
- Schwinn DA, Correa-Sales C, Page SO, Maze M. Functional effects of activation of alpha-1 adrenoceptors by dexmedetomidine: in vivo and in vitro studies. *The Journal of pharmacology and experimental therapeutics*. 1991; 259:1147–1152. [PubMed: 1684815]
- Shih T, McDonough JH Jr, Koplovitz I. Anticonvulsants for soman-induced seizure activity. *Journal of biomedical science*. 1999; 6:86–96. [PubMed: 10087439]
- Shouse MN, Langer J, Bier M, Farber PR, Alcalde O, Moghimi R, Richkind M, Szymusiak R. The alpha 2-adrenoreceptor agonist clonidine suppresses seizures, whereas the alpha 2-adrenoreceptor antagonist idazoxan promotes seizures in amygdala-kindled kittens: a comparison of amygdala and pontine microinfusion effects. *Epilepsia*. 1996; 37:709–717. [PubMed: 8764807]
- Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W, Investigators N. Intramuscular versus intravenous therapy for prehospital status epilepticus. *The New England journal of medicine*. 2012; 366:591–600. [PubMed: 22335736]
- Siso S, Hobson BA, Harvey DJ, Bruun DA, Rowland DJ, Garbow JR, Lein PJ. Spatiotemporal Progression and Remission of Lesions in the Rat Brain Following Acute Intoxication with Diisopropylfluorophosphate. *Toxicological sciences: an official journal of the Society of Toxicology*. 2017
- Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA, Palmiter RD. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 1999; 19:10985–10992. [PubMed: 10594079]
- Tanaka K, Oda Y, Funao T, Takahashi R, Hamaoka N, Asada A. Dexmedetomidine decreases the convulsive potency of bupivacaine and levobupivacaine in rats: involvement of alpha2-adrenoceptor for controlling convulsions. *Anesthesia and analgesia*. 2005; 100:687–696. table of contents. [PubMed: 15728053]
- Tarkovacs G, Rakovska A, Romics L, Vizi ES. Presynaptic effect of dexmedetomidine on cholinergic chemical transmission. *Acta physiologica Hungarica*. 1990; 75(Suppl):275–276. [PubMed: 1973570]
- Trinka E, Hofler J, Leitinger M, Brigo F. Pharmacotherapy for Status Epilepticus. *Drugs*. 2015; 75:1499–1521. [PubMed: 26310189]
- Walton NY, Treiman DM. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. *Experimental neurology*. 1988; 101:267–275. [PubMed: 3396644]
- Wang R, Macmillan LB, Freneau RT Jr, Magnuson MA, Lindner J, Limbird LE. Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5' regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals. *Neuroscience*. 1996; 74:199–218. [PubMed: 8843087]
- Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. *Epilepsia*. 2011; 52(Suppl 8): 70–71.
- Watkins J, FitzGerald G, Zamboulis C, Brown MJ, Dollery CT. Absence of opiate and histamine H2 receptor-mediated effects of clonidine. *Clinical pharmacology and therapeutics*. 1980; 28:605–610. [PubMed: 6254720]

- Weinshenker D, Szot P. The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. *Pharmacology & therapeutics*. 2002; 94:213–233. [PubMed: 12113799]
- White AM, Williams PA, Ferraro DJ, Clark S, Kadam SD, Dudek FE, Staley KJ. Efficient unsupervised algorithms for the detection of seizures in continuous EEG recording from rats after brain injury. *J Neurosci Methods*. 2006; 152:255–266. [PubMed: 16337006]
- Whittington RA, Virag L, Vulliemoz Y, Cooper TB, Morishima HO. Dexmedetomidine increases the cocaine seizure threshold in rats. *Anesthesiology*. 2002; 97:693–700. [PubMed: 12218537]
- Yakoub LK, Mohammad FK. Medetomidine protection against diazinon-induced toxicosis in mice. *Toxicology letters*. 1997; 93:1–8. [PubMed: 9381477]
- Yoo H, Iiro T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. *European journal of clinical pharmacology*. 2015; 71:1197–1207. [PubMed: 26233335]
- Zhai MZ, Wu HH, Yin JB, Cui YY, Mei XP, Zhang H, Zhu X, Shen XF, Kaye AD, Chen GZ. Dexmedetomidine Dose-Dependently Attenuates Ropivacaine-Induced Seizures and Negative Emotions Via Inhibiting Phosphorylation of Amygdala Extracellular Signal-Regulated Kinase in Mice. *Molecular neurobiology*. 2016; 53:2636–2646. [PubMed: 26099305]
- Zhou X, Wang T, Huang S. Effects of the menstrual cycle on bispectral index and anesthetic requirement in patients with preoperative intravenous dexmedetomidine following propofol induction. *Int J Clin Exp Med*. 2014; 7:5663–5668. [PubMed: 25664087]

Highlights

- Nerve agent-induced status epilepticus becomes refractory to midazolam
- Combined therapy with dexmedetomidine and midazolam stops status epilepticus
- Dexmedetomidine prevents excitotoxicity in amygdala, thalamus, and piriform cortex
- Atipamezole blocks but does not reverse the protective effects of dexmedetomidine

Figure 1. Treatment with MDZ + DEX at 20 minutes after SE onset

Pictured are representative EEG traces from animals treated with MDZ + Saline or MDZ + 0.4 mg/kg DEX. Red lines indicate treatment time. Green arrows indicate the location of insets at right. Scale bars for the insets are 2 seconds in the x direction and 0.5 mV in the y direction. The change in spike rate and gamma power relative to baseline for each treatment group is plotted as mean $\pm$ standard error. Hours in which a significant effect of treatment was observed are marked with an asterisk.

Figure 2. Treatment with MDZ + DEX at 40 minutes after SE onset

Pictured are representative EEG traces from animals treated with MDZ + Saline or MDZ + 0.4 mg/kg DEX. Red lines indicate treatment time. Green arrows indicate the location of insets at right. Scale bars for the insets are 2 seconds in the x direction and 0.5 mV in the y direction. The change in spike rate and gamma power relative to baseline for each treatment group is plotted as mean $\pm$ standard error. Hours in which a significant effect of treatment was observed are marked with an asterisk.

Figure 3. Treatment with DEX alone at 20 minutes after SE onset

Pictured is a representative EEG trace from an animal treated with 0.4 mg/kg DEX alone. The red line indicates treatment time. Green arrows indicate the location of insets at right. Scale bars for the insets are 2 seconds in the x direction and 0.5 mV in the y direction. The change in spike rate and gamma power relative to baseline for each treatment group is plotted as mean $\pm$ standard error. Hours in which a significant effect of treatment was observed are marked with an asterisk.

Figure 4. Blocking of MDZ + DEX with ATI

Pictured are representative EEG traces from animals treated with ATI five minutes prior to MDZ + 0.4 mg/kg DEX. In the majority of animals, SE persisted and in a single animal, SE stopped. Blue lines indicate ATI administration time and red lines indicate MDZ + DEX administration time. Green arrows indicate the location of insets at right. Scale bars for the insets are 2 seconds in the x direction and 0.5 mV in the y direction. The change in spike rate and gamma power relative to baseline for each treatment group is plotted as mean $\pm$ standard error. Hours in which a significant effect of treatment was observed are marked with an asterisk.

Figure 5. Reversal of MDZ + DEX with ATI

Pictured are representative EEG traces from animals treated with ATI ten minutes after MDZ + 0.4 mg/kg DEX had already stopped SE. In the majority of animals, SE did not return and in a subset of animals, SE did return. Blue lines indicate ATI administration time and red lines indicate MDZ + DEX administration time. Green arrows indicate the location of insets at right. Scale bars for the insets are 2 seconds in the x direction and 0.5 mV in the y direction. The change in spike rate and gamma power relative to baseline for each treatment group is plotted as mean $\pm$ standard error. Hours in which a significant effect of treatment was observed are marked with an asterisk.

Figure 6. FluoroJade B counts in susceptible brain regions for all treatment groups

Counting regions were defined as outlined. FluoroJade B counts for each treatment group in each brain region are presented as mean $\pm$ standard error. Groups that were different from MDZ + saline at the same time point are marked with an asterisk.

Table 1

Anticonvulsant outcomes for animals treated 20 or 40 minutes after SE onset

Treatment Group	No. of Subjects with No SE Termination	No. of Subjects with Temporary SE Termination	No. of Subjects with Lasting SE Termination	Latency to Termination
MDZ + Saline @ 20 min (n=12)	11	1	0	124 min
MDZ + 0.1 mg/kg DEX @ 20 min (n=9)	3	4	2	29 ± 10 min
MDZ + 0.2 mg/kg DEX @ 20 min (n=12)	2	8	2	25 ± 7 min
MDZ + 0.4 mg/kg DEX @ 20 min (n=9)	0	4	5	16 ± 9 min
MDZ + Saline @ 40 min (n = 9)	9	0	0	NA
MDZ + 0.4 mg/kg DEX @ 40 min (n=8)	2	6	0	35 ± 3 min
0.4 mg/kg DEX alone @ 20 min (n = 10)	7	3	0	142 ± 20 min

Table 2

p-values for spike rate comparisons

	20 min Pre-SE	At Treatment	Hour 1	Hour 2	Hour 3	Hour 4
Overall ANOVA	0.9507	0.8043	p < 0.0001	p < 0.0001	p < 0.0001	p < 0.0001
MDZ + Saline vs. MDZ + 0.1 mg/kg DEX	--	--	p < 0.01	p < 0.05	ns	ns
MDZ + Saline vs. MDZ + 0.2 mg/kg DEX	--	--	p < 0.001	p < 0.001	p < 0.001	p < 0.01
MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	--	--	p < 0.001	p < 0.001	p < 0.001	p < 0.001
MDZ + 0.1 mg/kg DEX vs. MDZ + 0.2 mg/kg DEX	--	--	ns	p < 0.05	p < 0.05	p < 0.05
MDZ + 0.1 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	--	--	p < 0.01	p < 0.01	p < 0.001	p < 0.001
MDZ + 0.2 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	--	--	ns	ns	ns	ns
MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	p < 0.05	p < 0.05	0.8257	p < 0.01	p < 0.05	0.1199
MDZ + Saline vs. 0.4 mg/kg DEX alone	0.5742	0.5294	0.1274	0.4061	p < 0.01	p < 0.001
Overall ANOVA	0.5817	0.7508	p < 0.0001	p < 0.0001	p < 0.001	p < 0.01
MDZ + Saline vs. Blocking	--	--	p < 0.01	p < 0.01	ns	ns
MDZ + 0.4 mg/kg DEX vs. Blocking	--	--	ns	ns	ns	ns
Overall ANOVA	0.9557	0.9799	p < 0.0001	p < 0.0001	p < 0.001	p < 0.01
MDZ + Saline vs. Reversal	--	--	p < 0.001	p < 0.01	ns	ns
MDZ + 0.4 mg/kg DEX vs. Reversal	--	--	ns	ns	ns	ns

Table 3

p-values for gamma power comparisons

	20 min Pre-SE	At Treatment	Hour 1	Hour 2	Hour 3	Hour 4
Overall ANOVA	0.8233	0.7397	p < 0.0001	p < 0.0001	p < 0.0001	p < 0.0001
MDZ + Saline vs. MDZ + 0.1 mg/kg DEX	--	--	p < 0.05	p < 0.05	ns	ns
MDZ + Saline vs. MDZ + 0.2 mg/kg DEX	--	--	p < 0.001	p < 0.001	p < 0.001	p < 0.001
MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	--	--	p < 0.001	p < 0.001	p < 0.001	p < 0.001
MDZ + 0.1 mg/kg DEX vs. MDZ + 0.2 mg/kg DEX	--	--	ns	p < 0.05	p < 0.01	p < 0.001
MDZ + 0.1 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	--	--	p < 0.05	p < 0.01	p < 0.001	p < 0.001
MDZ + 0.2 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	--	--	ns	ns	ns	ns
MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	0.0777	0.3828	0.2938	p < 0.001	p < 0.001	p < 0.01
MDZ + Saline vs. 0.4 mg/kg DEX alone	0.3818	0.3534	p < 0.01	0.2139	p < 0.05	p < 0.001
Overall ANOVA	0.1091	0.1449	p < 0.0001	p < 0.0001	p < 0.0001	p < 0.0001
MDZ + Saline vs. Blocking	--	--	p < 0.05	p < 0.01	p < 0.05	ns
MDZ + 0.4 mg/kg DEX vs. Blocking	--	--	p < 0.01	p < 0.01	p < 0.001	p < 0.01
Overall ANOVA	0.8118	0.4191	p < 0.0001	p < 0.0001	p < 0.0001	p < 0.0001
MDZ + Saline vs. Reversal	--	--	p < 0.001	p < 0.001	p < 0.01	p < 0.05
MDZ + 0.4 mg/kg DEX vs. Reversal	--	--	p < 0.01	p < 0.001	p < 0.001	p < 0.001

Table 4

p-values for histology comparisons

		Amygdala	Thalamus	Piriform Cortex	Hippocampus	Parietal Cortex
20 Min	Overall ANOVA	p < 0.0001	p < 0.0001	p < 0.0001	0.5754	0.8153
	MDZ + Saline vs. MDZ + 0.1 mg/kg DEX	p < 0.001	p < 0.001	p < 0.001	--	--
	MDZ + Saline vs. MDZ + 0.2 mg/kg DEX	p < 0.001	p < 0.001	p < 0.001	--	--
	MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	p < 0.001	p < 0.001	p < 0.001	--	--
	MDZ + 0.1 mg/kg DEX vs. MDZ + 0.2 mg/kg DEX	ns	ns	ns	--	--
	MDZ + 0.1 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	ns	ns	ns	--	--
	MDZ + 0.2 mg/kg DEX vs. MDZ + 0.4 mg/kg DEX	ns	ns	ns	--	--
	MDZ + Saline vs. MDZ + 0.4 mg/kg DEX	p < 0.0001	p < 0.001	p < 0.01	0.3558	0.1516
	MDZ + Saline vs. 0.4 mg/kg DEX alone	p < 0.05	p < 0.01	0.0619	0.4757	0.5350
	Overall ANOVA	p < 0.0001	p < 0.0001	p < 0.0001	0.4955	0.3479
Blocking	MDZ + Saline vs. Blocking	ns	p < 0.05	ns	--	--
	MDZ + 0.4 mg/kg DEX vs. Blocking	p < 0.05	ns	p < 0.05	--	--
Reversal	Overall ANOVA	p < 0.0001	p < 0.0001	p < 0.001	0.4583	0.5847
	MDZ + Saline vs. Reversal	p < 0.01	p < 0.001	p < 0.05	--	--
	MDZ + 0.4 mg/kg DEX vs. Reversal	ns	ns	ns	--	--